Fas ligand in human serum

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Fas ligand (FasL) induces apoptosis in target cells.
• FasL can be converted from a membrane-bound to a soluble form (sFasL).

Purpose of the Study:

• To investigate the role of sFasL in large granular lymphocytic (LGL) leukemia and natural killer (NK) cell lymphoma.
• To develop methods for detecting and neutralizing sFasL.

Main Methods:

• Developed two neutralizing monoclonal anti-human FasL antibodies.
• Established an enzyme-linked immunosorbent assay (ELISA) for sFasL detection in human sera.
• Analyzed FasL expression on malignant cells and healthy NK cells.

Main Results:

• Healthy sera showed no detectable sFasL; LGL leukemia and NK cell lymphoma sera were positive.
• Malignant cells constitutively expressed FasL, while healthy NK cells expressed it upon activation.
• sFasL is produced by malignant cells in these conditions.

Conclusions:

• Elevated sFasL in LGL leukemia and NK cell lymphoma contributes to systemic tissue damage.
• Neutralizing anti-FasL antibodies or matrix metalloproteinase inhibitors are potential therapeutic strategies.